REVBW — Revelation Biosciences Inc
NASDAQ
$0.01
+$0.00 (+47.76%)
Revelation Biosciences Inc (REVBW) common stock listed on NASDAQ. It is led by James M. Rolke, based in 4660 La Jolla Village Drive, San Diego, CA, United States, 92122, with about 8 employees. Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Net income was -$1.9M.
Use this REVBW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the REVBW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the REVBW SEC filings page. Lician reads the product cache first so this HTML stays unique to Revelation Biosciences Inc even when a live quote feed is slow.
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
REVBW Key Statistics
Market Cap
$0.00M
Volume
249
Previous Close
$0.01
Day Range
$0.01 – $0.01
EPS
-$87.68
Revenue
$0.00
Net Income
-$15.04M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
8
REVBW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$15.04M | -$120.25K | -$10.83M | -$2.13M |
| EPS (Diluted) | -$87.68 | -$8.44 | -$149.20 | -$42.50 |
Total Assets
$6.62M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$6.50M
Operating Cash Flow
-$18.32M
Free Cash Flow
$0.00
Revelation Biosciences Inc Company Information
- Chairman & CEO
- James M. Rolke
- Headquarters
- 4660 La Jolla Village Drive, San Diego, CA, United States, 92122
- Website
- www.revbiosciences.com
- Phone
- 650 800 3717
- IPO / Founded
- 2020-11-16